Evidence map›Paper›PMID 42751164›Full record

ArticleMaterials today. Bio2026

A transdermal CRISPR/Cas9 strategy using biodegradable microneedles to target YB-1 in melanoma.

Xiazhou Fu, Zhaoyi Chen, Ziru Zhang, Yufei Jiang, Xiaomeng Jiang, Yuxin Yang, Hongsheng Zhang, Xinyun Zou, Jingwen Luo

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Materials today. Bio, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Xiazhou FuState Key Laboratory of Oral & Maxillofacial Reconstruction and Regeneration, Key Laboratory of Oral Biomedicine Ministry of Education, Hubei Key Laboratory of Stomatology, School & Hospital of Stomatology, Wuhan University, Wuhan, 430072, China.
Zhaoyi ChenState Key Laboratory of Oral & Maxillofacial Reconstruction and Regeneration, Key Laboratory of Oral Biomedicine Ministry of Education, Hubei Key Laboratory of Stomatology, School & Hospital of Stomatology, Wuhan University, Wuhan, 430072, China.
Ziru ZhangHubei Province Key Laboratory of Industrial Biotechnology, School of Life Sciences, Hubei University, Wuhan, 430062, China.
Yufei JiangHubei Province Key Laboratory of Industrial Biotechnology, School of Life Sciences, Hubei University, Wuhan, 430062, China.
Xiaomeng JiangHubei Province Key Laboratory of Industrial Biotechnology, School of Life Sciences, Hubei University, Wuhan, 430062, China.
Yuxin YangHubei Province Key Laboratory of Industrial Biotechnology, School of Life Sciences, Hubei University, Wuhan, 430062, China.
Hongsheng ZhangHubei Province Key Laboratory of Industrial Biotechnology, School of Life Sciences, Hubei University, Wuhan, 430062, China.
Xinyun ZouHubei Province Key Laboratory of Industrial Biotechnology, School of Life Sciences, Hubei University, Wuhan, 430062, China.
Jingwen LuoHubei Province Key Laboratory of Industrial Biotechnology, School of Life Sciences, Hubei University, Wuhan, 430062, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Melanoma's aggressiveness and therapeutic resistance highlight the need for innovative strategies. This study developed a CRISPR/Cas9 ribonucleoprotein (RNP) system targeting the oncogenic YB-1 gene, combined with doxorubicin (DOX), delivered by chondroitin sulfate (CS)-based microneedles (MN) incorporating designed nanoparticles (CNPs). YB-1, a critical oncogene driving melanoma progression, metastasis, and drug resistance, was targeted to enhance therapy efficacy.

Indexed as

ChemotherapyCRISPR/Cas9Gene therapyMicroneedleTransdermal drug delivery

Identifiers

PMID42751164
PMCPMC13579312

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.